SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC14D9C - Written communication relating to third party tender offer:
SEC Accession No. 0001193125-22-286794
Filing Date
2022-11-16
Accepted
2022-11-16 16:24:31
Documents
3

Document Format Files

Seq Description Document Type Size
1 SC14D9C d396331dsc14d9c.htm SC14D9C 23236
2 EX-99.1 d396331dex991.htm EX-99.1 18013
3 EX-99.2 d396331dex992.htm EX-99.2 13913
  Complete submission text file 0001193125-22-286794.txt   56801
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filed by) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Subject) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C | Act: 34 | File No.: 005-91186 | Film No.: 221395459
SIC: 2836 Biological Products, (No Diagnostic Substances)